Category: Guided Therapeutics Inc.
As requested, Guided Therapeutics gets a sit-down with the FDA to discuss a renewed bid to land approval for its LuViva cervical scanner.
Guided Therapeutics (OTC:GTHP) is getting its requested date with the FDA's medical device regulators, during which the company hopes to revive its rejected bid to win approval for the LuViva cervical scanner.
Here's a look at some of the top regulatory stories for medical device companies this week.
Guided Therapeutics asks the FDA for a face-to-face meeting to discuss the revival of its approval bid for the LuViva cervical scanner.
Guided Therapeutics (OTC:GTHP) said it's asked the FDA for a face-to-face meeting as it tries to resurrect the pre-market approval application for its LuViva cervical scanning device.
Philips names Brent Shafer its new CEO for North America, promoting him from chief of the home healthcare solutions group.
Technology giant Philips (NYSE:PHG) named a new North America CEO this week, promoting home health solutions chief Brent Shafer to replace Greg Sebasky, who retired this week.
Guided Therapeutics signs distribution deals to gain access to 86 million new potential patients, hoping to land a win after the FDA refused to accept the company's premarket approval application.
Georgie-based Guided Therapeutics (OTC:GTHP) hasn't won many points after announcing increased distribution for its LuViva advanced cervical scanning system.
Guided Therapeutics shares drop nearly 20% as the company faces more regulatory setbacks in getting its LuViva advanced cervical scanning system onto the U.S. market.
AngioDynamics lets U.S. sales general manager Alan Panzer go "without cause."
keys: angiodynamics, cfo, alan panzer
Albany, N.Y.-based AngioDynamics (NSDQ:ANGO) said Alan Panzer, its general manager of U.S. sales, will no longer be with the company as of July 31, 2013.